Figure S1. Differential effects of type I PRMT versus PRMT5 inhibitors.

(A) MKL-1 cells were treated with DMSO or 12 nM JNJ-64619178 for 5 d, then stained with 0.01 μM calcein AM and 100 ng/ml ethidium homodimer-1 (EthD-1) to detect live (green) and dead (red) cells, respectively. (B) MKL-1 cells were treated with PRMT5 inhibitor JNJ-64619178 at 12, 111, or 1,000 nM for 1, 2, 3, or 4 d, and the levels of SDMA, ADMA, and MMA were evaluated. (C) MKL-1 cells were treated with serially diluted concentrations of another PRMT5 inhibitor (LLY-283) for 4 d, then assessed for arginine modifications. (D) MKL-1 cells were treated with LLY-283 for 4, 6, or 8 d, and cell viability was measured using the CellTiter-Glo assay. (E) MKL-1 cells were treated with pan–type I PRMT inhibitor MS023 (which does not target PRMT5, a type II PRMT) for 5, 8, or 11 d, and cell viability was measured with CellTiter-Glo. (F) MKL-1 cells were treated with MS023 and examined for arginine modifications. (G) MKL-1 cell line with Dox-inducible EP400 shRNA was treated with Dox, 12 nM JNJ-64619178, or both, and immunoblotted for various histone marks. (H) Same Dox-inducible EP400 shRNA MKL-1 cell line was treated with Dox, 0.3 nM JNJ-64619178, or both, then immunoblotted for various histone marks.

Source data are available for this figure.